Cinnamomi Ramulus Inhibits the Growth of Colon Cancer Cells Via Akt/ERK Signaling Pathways

Boyu Pan

Tianjin University

Yafei Xia

Tianjin University

Zilu Gao

Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Gang Zhao

Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Liangjiao Wang

Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Senbiao Fang

Central South University

Liren Liu (✉ liuliren@tjmuch.com)

Tianjin Medical University Cancer Institute and Hospital: Tianjin Tumor Hospital

Shu Yan

Tianjin University

Research

Keywords: Cinnamomi Ramulus (CR), Colon cancer (CC), Chinese herb medicine (CHM), network pharmacology, bioinformatics, Akt/ERK signaling pathways

Posted Date: November 23rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1086194/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Chinese Medicine on March 9th, 2022. See the published version at <https://doi.org/10.1186/s13020-022-00588-6>.

Abstract

Background

Colon cancer (CC) has the second highest mortality rate among malignant tumors worldwide, and the current mainstream treatment regimens are not very effective. The unique efficacy of Chinese herb medicine (CHM) for cancers has recently received increasing attention. *Cinnamomi Ramulus* (CR), as a classic CHM, has been widely used in the treatment of a variety of diseases for hundreds of years in China, but its specific pharmacological mechanism of against CC still needs to be fully evaluated.

Methods

TCMSP and China National Knowledge Infrastructure database were obtained to predict the candidate ingredients of CR, and TCMSP and SwissTargetPrediction database were also employed to predict the drug targets of the candidate ingredients from CR. Then, we evaluated the therapeutic effect of CR on CC by oral administration in CC-bearing mice and performed *in vitro* cellular functional verifications. Next, the potential CC-related targets were further identified by using Gene Expression Omnibus (GEO) database. Based on these obtained targets, the drug/disease-target PPI networks were constructed using Bisogenet plugin of Cytoscape. The potential core therapeutic targets were then identified through topological analysis using CytoNCA plugin. GO and KEGG enrichment analyses were performed to predict the underlying mechanism of CR against CC. Furthermore, these *in silico* analysis results were validated by a series of cellular functional and molecular biological assays.

Results

In this study, we first found that CR has potential therapeutic effects on cancers. Then, oral administration of CR could inhibit the growth of CC cells in C57BL/6 mice, and it could inhibit the viability and motility of CC cells. Meanwhile, we further obtained 111 potential core therapeutic targets, and enrichment analyses showed that CR could induce the apoptosis and cell cycle arrest in CC cells by blocking the Akt/ERK signaling pathways. The above virtual results were further verified. Next, we used ultraperformance liquid chromatography-tandem mass spectrometry (UPLC–MS/MS) to identify 5 key components from the crude extract of CR. Molecular docking analysis revealed that taxifolin is mostly likely to be a potential key active ingredient.

Conclusions

In summary, our results indicate that CR has good prospects in the treatment of CC.

Background

Colon cancer (CC) is currently one of the five major malignant tumors in the world. According to cancer statistics published by the American Cancer Society, the mortality rate of CC has reached 9.2%, increasing to

second among all cancer types^[1–3]. Currently, tumor resection, chemotherapy, radiofrequency ablation, and targeted therapy are still the mainstream treatment methods for CC^[4]. However, the overall efficacy of these treatments is not satisfactory^[5]. Therefore, there is an urgent need to find new treatments to improve the survival and prognosis of CC patients.

As an important component of traditional Chinese medicine (TCM), Chinese herbal medicine (CHM) has been widely used in the treatment of various diseases in China for thousands of years. Recent studies have shown that CHM provides a key option for the treatment of complex diseases, including cancer, due to its unique clinical efficacy^[6, 7]. *Cinnamomi Ramulus* (CR, Chinese name: Guizhi), the dried branch of cinnamon, is an important representative of CHM. It first appeared in China's classic Han dynasty medical treatise *Shang Han Lun* (Treatise on Cold Damage) (Figure 1A). In TCM theory, CR induces sweating and relieves exterior syndromes, dissipates cold and relieves pain, promotes yang and transforms qi. Modern pharmacology has confirmed that CR has antibacterial, antiinflammatory, antiviral, hypoglycemic and antiplatelet agglutination effects^[8]. Since 1973, CR has been listed as an important TCM by the *Chinese Pharmacopoeia* due to its definite efficacy, minimal toxic side effects, and stable quality. Additionally, more than 60 types of Chinese medicine preparations containing CR (e.g. Danggui Sini Decoction and Huangqi Guizhi Wuwu Decoction) have been included in the *Chinese Pharmacopoeia*^[8]. Recent studies have shown that some TCM formulas containing CR have good antitumor effects. Dai et al. reported that Guizhi Fuling Decoction could play a role in the treatment of breast cancer by interfering with the phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling pathways^[9]. Another study showed that Danggui Sini Decoction, a traditional classic recipe, could affect some key biological processes, such as apoptosis and the cell cycle, involved in the survival and growth of gastric cancer cells. The disruption of these biological processes may be attributed to the simultaneous inhibition of a variety of molecular signaling pathways, including the PI3K/Akt, MAPK, and p53 pathways^[10].

In recent years, network pharmacology has gradually become a promising method for studying TCM from a systematic perspective^[11]. The network pharmacology of TCM integrates pharmacology, phytochemistry, bioinformatics, and computational biology techniques. These methods help to study the pharmacological mechanism of TCM and bridge the gap between Western medicine and TCM^[12, 13]. The results of several previous studies have shown that some components from CR have potential therapeutic effects on CC^[14, 15]. However, the overall pharmacological mechanism of CR in anti-CC and its potential clinical application value need to be fully evaluated. Therefore, we conducted this study guided by TCM network pharmacology, bioinformatics, and molecular docking analysis. Through a series of *in vivo* and *in vitro* experiments, we demonstrated that CR can exert a significant direct inhibitory effect on the growth of CC cells by blocking the Akt/ERK signaling pathway.

Methods

Cell culture and related reagents

HT-29 and HCT-15 human colon carcinoma cells and MC-38 murine colon carcinoma cells were purchased from China Infrastructure of Cell Line Resources (China) and then cultured in DMEM and RPMI-160 medium,

respectively, supplemented with 10% (v/v) fetal bovine serum (FBS) and 100 U/ml streptomycin/penicillin at 37°C and 5% CO₂. Cell Counting Kit-8 (CCK-8) reagent was purchased from Dojindo (Japan). Hoechst 33342 reagent was purchased from Beyotime (China). An Annexin-V FITC apoptosis detection kit (#556547) and FITC BrdU cycle detection kit Part A (#559619) were purchased from BD Biosciences PharMingen (USA). Antibodies against Bcl-2, Bax, caspase 9/p35/p10, poly (ADP-ribose) polymerase-1 (PARP1), cyclin D1, and beta-actin were purchased from Proteintech. Antibodies against cyclin A2, cyclin B1, p-Akt (S473), p-Akt (T308) and p-ERK (T202/Y204) were purchased from CST. Antibody against CDK2 was purchased from Abcam. CR powder was provided by the Chinese Medicine Pharmacy of Tianjin Medical University Cancer Institute and Hospital. The concentration of the prepared CR solution was 0.05 g/ml. In addition, for the subsequent relevant biological experiments, the 0.05 g/ml solution was subjected to 0.22 µm filter membrane filtration and sterilization and dilution to the necessary concentrations.

Screening of potential active components in CR

The traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) is a database and visualization platform established based on the pharmacology framework of the CHM system (<http://tcmssp.com/tcmssp.php>). It includes 499 CHMs, 29,384 components, 3311 targets, and 837 related diseases registered in the *Chinese Pharmacopoeia*^[16]. In this study, the main active compounds of CR were first searched through the TCMSP online platform, with "*Cinnamomi Ramulus*" as the key word, and then, all the compounds obtained in the search were then screened for potential activity based on absorption, distribution, metabolism, and elimination (ADME)-related parameters. The parameters were set as oral bioavailability (OB) ≥ 30% and drug-like activity (DL) ≥ 0.18, and the relevant active ingredients were obtained after screening. In addition, we also searched the China National Knowledge Infrastructure (www.CNKI.net) to obtain the main active components in CR; however, not all of the abovementioned parameters were met.

Screening of potential drug targets corresponding to CR and disease targets closely related to CC

First, TCMSP and the SwissTargetPrediction database (<http://www.swisstargetprediction.ch/>) were used to query the drug targets corresponding to the potential active compounds of CR obtained via the abovementioned methodology. The UniProt online database (<http://www.uniprot.org/>) was used to query the gene name corresponding to each protein target, verify the species origin as "human" and create a dataset for subsequent analysis. Additionally, we obtained the known disease targets closely related to CC from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>), which includes two gene expression dataset microarrays (GSE44076 and GSE13471) from human-derived CC and adjacent normal tissues. Then, the protein-protein interaction (PPI) data were analyzed using the core plugin Bisogenet in Cytoscape software. The final results were integrated into a single result for six independent analyses of the PPI data obtained above.

Systematic network construction and enrichment analysis

We first constructed PPI network relationships between candidate drug targets of CR and disease targets associated with CC through the Bisogenet and visualized the images with Cytoscape software (Version 3.2.1)^[17]. Then, the above 2 PPI networks were merged, and the topological parameters of each node in the merged

network were calculated using CytoNCA, another Cytoscape plugin. In the merged network system, the nodes with twice the median of 'degree centrality' (DC) were considered important nodes, and then, these nodes were used to generate a new relational network. Next, to further screen the potential core targets of CR for the treatment of CC, we mined the topological parameters of the new network that were higher than the 'DC', 'betweenness centrality' (BC) and 'closeness centrality' (CC) medians. These targets were considered to be the most significant among all nodes. Then, we used KOBAS 3.0 (<http://kobas.cbi.pku.edu.cn/>), The Database for Annotation, Visualization and Integrated Discovery (DAVID) v 6.8 (<https://david.ncifcrf.gov/>) and Metascape (<https://metascape.org/>) to conduct the enrichment analysis of biological functions and signaling pathways for the obtained candidate drug targets and core targets.

Mouse xenograft experiment

Four-week-old male C57BL/6 mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (China). All procedures involving animals were performed in accordance with the regulations of the Ethics Committee of the Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Tianjin University (ITCWM Hospital, Tianjin University). Ten animals were randomly divided into 2 groups, with 5 animals in each group. At 5 weeks of age, MC-38 murine colon carcinoma cells (1.0×10^6 /100 μ L) transfected with a luciferase reporter plasmid were subcutaneously injected into the right hip area of the 10 mice using a 1-ml needle. After 10 days, when tumors were visible to the naked eye, 200 μ L of normal saline (blank control group) or CR solution (300 mg/kg body weight) was administered to the mice by gavage (po) twice daily during the experimental period (drug administration was performed in the morning/afternoon). The tumor volume was calculated once per day using the following formula: long diameter $\times$ (short diameter)² / 2. On day 14, tumor-bearing mice were observed and photographed using a small animal imaging system. Then, all mice were sacrificed, and tumor tissue was weighed. None of the mice died before the end of the experimental period.

Immunohistochemistry

Slides containing tumor tissue were deparaffinized, and antigen retrieval was performed. Then, the slides were incubated with anti-Ki-67 antibody (Abcam, UK) overnight at 4°C. After washing with phosphate buffered saline (PBS), the slides were incubated with Polymer Helper and poly peroxidase-anti-mouse/rabbit IgG (PV-9000, ORIGENE, China) and then further incubated with diaminobenzidine (DAB).

Cell function and molecular mechanism verifications

The procedures for assessing cell viability and plate colony formation were described previously^[18, 19]. The cumulative motility of CC cells was calculated using an Operetta CLSTM high-content analysis system equipped with Harmony software (Perkin Elmer, Waltham, MA, USA). The measurement was performed in digital phase contrast mode at 37°C and 5% CO₂ using a $\times 20$ long distance objective. In addition, apoptosis and cell cycle assays and western blots (WBs) were performed^[18].

High-performance liquid chromatography coupled with mass spectrometry and sample extraction

High-performance liquid chromatographic separation and mass spectrometric detection were performed using Waters Quattro Premier XE/Acquity UPLC system coupled to a tandem quadrupole mass spectrometer (Waters

Corporation, Milford, MA, United States). Lab solutions LCMS software (Masslynx V4.1) was used to control the instruments and process the data. Please see details as we previously described^[19].

Molecular docking analysis

AutoDock software (v4.2) was used to dock the structures of five ingredients, including cinnamic acid, 2-Hydroxycinnamic acid, protocatechuic acid, catechinic acid and taxifolin in *Cinnamomi Ramulus* detected by UPLC-MS/MS. These ingredients were docked with PRKCA (PDB code: 4DNL), HSP90AB1 (PDB code: 1UYM), APP (AlphaFold code: P05067), RELA (PDB code: 2O61), JUN (AlphaFold code: P05412), MDM2 (PDB code: 1T4E), PRKACA (PDB code: 2GU8), HSPA1A (PDB code: 1HJO) and PARP1 (PDB code: 1UK0), respectively. Please see details as we previously described^[10].

Statistical analyses

All data were analyzed using SPSS 17.0 software (USA). Results were represented as mean with standard deviations (mean $\pm$ SD). The differences expressed were using the Student's *t*-test, and *p*<0.05 was considered as statistically significant.

Results

Screening and enrichment analysis of candidate active components and potential drug targets of CR

To investigate the pharmacological action mechanism of CR, we first performed virtual screening based on the two important parameters of ADME, i.e., OB and DL, to obtain the potential active components in CR. Seven monomers met the requirements of OB $\geq$ 30% and DL $\geq$ 0.18. Then, we also identified seven other monomeric components that either showed good pharmacological activity or were typical main components of CR reported in the literature. They were included for subsequent analysis; however, for the components, either OB was less than 30% or DL was less than 0.18. Therefore, a total of 14 compounds were considered potential monomerically active components of CR (Figure 1B & Table 1).

Table 1
The specific information of candidate active ingredients in CR obtained from a virtual screening and literature mining.

MOL number	Candidate ingredients	OB/%	DL
MOL000019	D-Camphene	34.98	0.04
MOL000073	ent-Epicatechin	48.96	0.24
MOL000358	Beta-sitosterol	36.91	0.75
MOL000359	Sitosterol	36.91	0.75
MOL000492	(+)-Catechin	54.83	0.24
MOL000608	()-Terpinen-4-ol	81.41	0.03
MOL000708	Benzaldehyde	32.63	0.01
MOL000991	Cinnamaldehyde	31.99	0.02
MOL001736	(-)-Taxifolin	60.51	0.27
MOL002225	Styrone	38.35	0.02
MOL002295	Cinnamic acid	19.68	0.03
MOL003530	O-Methoxycinnamaldehyde	26.52	0.04
MOL004576	Ttaxifolin	57.84	0.27
MOL011169	Peroxyergosterol	44.39	0.82

Subsequently, we further used two online databases, i.e., TCMSP and SwissTargetPrediction, to explore the candidate drug targets of the above 14 compounds and obtained a total of 142 drug targets (Supplementary Table 1). Interestingly, there were many overlapping targets among the 14 different components, indicating that these compounds may play key roles in generating synergistic effects. Then, we further used Cytoscape 3.2.1 software to construct a drug-target network to visualize the interactions between this systems (Figure 1C).

Next, we performed enrichment analysis of the Kyoto Encyclopedia of Genes and Genomes (KEGG) molecular signaling pathways and disease types for the 142 drug targets that were obtained using DAVID v 6.8 and KOBAS 3.0 software, respectively. The results indicated that the above targets were significantly associated with “Pathways in cancer” and “Cancers” (Figure 1D & 1E). Therefore, these prediction results not only help reveal the pharmacological mechanism of CR but also suggest that CR has great potential in cancer treatment.

Oral administration of CR can inhibit the growth of CC cells in C57BL/6 mice

To investigate the direct tumor suppressor effect of CR *in vivo*, we assessed its specific effects on xenograft tumors in C57BL/6 mice (subcutaneously injected with MC-38 cells) (Figure 2A). As shown in Figure 2B and

2C, compared with the control, the oral administration of CR significantly inhibited the growth of MC38 xenograft tumors *in vivo*. By day 14, the tumor volume in the CR treatment group was approximately 2.6 times that in the control group ($p < 0.05$) (Figure 2D). Furthermore, there was a significant difference in tumor weight between these two groups ($p < 0.05$); however, there was no significant difference in the body weight of mice between these two groups (Figure 2E & 2F). Next, through hematoxylin and eosin (H&E) tissue staining, we found that compared with the control group, tumor tissue in the CR treatment group showed obvious necrotic cells; the subsequent immunohistochemical analysis showed that the number of Ki-67-positive cells was significantly reduced in the CR treatment group, thus indicating that CR had an antiproliferative effect on colon tumor cells (Figure 2G). Therefore, the above results provide convincing evidence that CR has direct anti-CC activity.

CR can significantly inhibit the viability and motility of CC cells

Subsequently, we performed a series of *in vitro* CR pharmacodynamics experiments using CC cells. The results of the CCK-8 assay showed that CR had a dose- and time-dependent inhibitory effect on the growth of HT-29, HCT-15 and MC-38 cells (Figure 3A). The half maximal inhibitory concentration (IC_{50}) analysis at 24 h showed that the IC_{50} values for CR in HT-29 and HCT-15 human colon carcinoma cells were 0.278 ± 0.019 mg/mL and 0.123 ± 0.014 mg/mL, respectively. The results of the subsequent cell growth experiments indicated that the viability of HT-29 and HCT-15 cells significantly decreased at 48 h compared with the control group (Figure 3B). Meanwhile, the cell colony formation assay showed that the colony formation ability of the cells decreased in a dose-dependent manner after 24 h of treatment with CR (Figure 3C). In addition, we also used a high-content microscope to track the motility of cells in real time. The average cumulative movement of the cells in the CR treatment group was less than the control group at 24 h, indicating that the cell viability in the CR treatment group was significantly inhibited (Figure 3D). Therefore, the above results indicate that CR has a direct inhibitory effect on the survival and motility of CC cells.

Construction of CR anti-CC PPI systematic network and core target enrichment analysis

With the help of network pharmacology and bioinformatics techniques, we used the Bisogenet plugin in Cytoscape 3.2.1 software to perform PPI analysis of the 142 potential drug therapeutic targets identified for CR. A total of 5,575 nodes and 103,469 edges were obtained. Then, through the GEO online database, the gene expression results of two microarrays of human CC and paired paracancerous tissues (GSE44076 and GSE13471) were downloaded and analyzed. After screening based on the conditions of $p < 0.01$ and fold change > 2 , 114 relevant disease targets corresponding to CC were identified (Figure 4A-4C & Supplementary Table 2). Subsequently, the Bisogenet plugin was used to perform a PPI analysis of the above 114 disease targets. A total of 2027 nodes and 34,539 edges were obtained. Subsequently, to more accurately predict the potential core targets of CR for the treatment of CC, we used the CytoNCA plugin in Cytoscape software to systematically integrate the PPI analysis results for the drug targets and the disease targets. The conditions 'DC' > 48 and 'DC' > 80 , 'BC' > 0.002 , and 'CC' > 0.478 were used to perform core mining of the integrated network at the topology level, and 111 potential core targets were predicted (Figure 5A & Supplementary Table 3).

To further predict the potential biological processes and related molecular mechanisms involving the abovementioned 111 core targets, we used Metascape and DAVID v6.8 to perform an enrichment analysis of the biological functions (GO-Biological Process, GO-BP) and molecular mechanisms (KEGG). The results of the GO-BP analysis indicated that the above targets were closely associated with processes such as “pathways in cancer”, “apoptotic signaling pathways”, and “cell cycle” (Figure 5B), and the results of the KEGG analysis indicated that the above targets were closely associated with mechanisms such as 'pathways in cancer', 'viral carcinogenesis', the 'cell cycle', the 'PI3K-Akt signaling pathway', and the 'MAPK signaling pathway' (Figure 5C). The results of these “virtual studies” provide clues for further revealing and verifying the pharmacological mechanism of CR in the treatment of CC.

CR can induce apoptosis and G2/M phase arrest in CC cells

Next, we conducted a series of cell function experiments to verify the results of the above enrichment analysis. First, compared with the control group, the cells after CR treatment showed typical characteristics of apoptosis, such as shrinkage, rounding, and loss of contrast. Meanwhile, fluorescence observation after Hoechst 33342 staining revealed that nuclei after CR treatment exhibited dense staining or dense fragmented staining (Figure 6A). In addition, the flow cytometry results indicated that the apoptotic cell population stained with Annexin-V FITC significantly increased in a dose-dependent manner after CR treatment (Figure 6B-6D). The WB results also indicated that CR promoted the accumulation (dose-dependent) of the proapoptotic protein Bax and cleaved caspase-9 and PARP and the downregulation of antiapoptotic protein Bcl-2 (Figure 6H & Supplementary Figure 1).

In addition, we also performed cell cycle analysis via BrdU incorporation and flow cytometry to evaluate the effect of CR on the cell cycle of CC cells. The results showed that CR treatment arrested the cells at the G2/M phase, thereby significantly inhibiting their growth and proliferation (Figure 6E-6G). The WB results confirmed the accumulation of the G2/M phase-specific marker cyclin B1 and the downregulation of cyclin D1, CDK2 and cyclin A2 in CR-treated CC cells (Figure 6H & Supplementary Figure 1). In summary, the above results all indicated that CR inhibited the growth of CC cells by inducing apoptosis and cell cycle arrest.

CR can inhibit the growth of CC cells by blocking the Akt/ERK signaling pathways

To further explore the potential molecular mechanism by which CR inhibits the growth of CC, we next examined the key signaling pathways involved in cell proliferation and viability. Among them, we selected the PI3K-Akt and MAPK signaling pathways based on the results of the KEGG pathway enrichment analysis. The WB results indicated that after CR treatment, the expression levels of key protein factors, such as p-Akt (T308 & S473) and p-ERK (T202/Y204), in the above pathways in the two CC cells were significantly inhibited (Figure 7 & Supplementary Figure 2). This result indicates that the effects of CR, i.e., inducing apoptosis and cell cycle arrest and inhibiting the growth of CC cells, may be the result of the simultaneous inhibition of the Akt/ERK signaling pathway, thus demonstrating once again that CHM has “multi-component, multi-target, and multi-function” pharmacological characteristics.

Taxifolin is a potential key active component of CR in the treatment of CC

Next, we used ultraperformance liquid chromatography-tandem mass spectrometry (UPLC–MS/MS) to identify the potential active components in CR. A total of 5 key components were identified from the crude extract of CR, i.e., cinnamic acid (t_R : 26.30 min), 2-hydroxycinnamic acid (t_R : 11.70 min), protocatechuic acid (t_R : 4.17 min), catechinic acid (t_R : 6.93 min), and taxifolin (t_R : 9.12 min) (Figure 8A & 8B & Table 2). Intriguingly, 3 of the 5 components detected above are potential active components that were previously screened based on ADME-related characteristics or literature searches, thus again confirming the reliability of the network pharmacology prediction method. To further explore the molecular mechanism by which CR affects CC at the protein level, we used AutoDock 4.2 software to perform molecular docking analysis between the above active ingredients and key targets. The key targets were obtained by combining the previously obtained 142 drug targets of CR with 111 core targets of CR for CC and identifying areas of overlap; ultimately, a total of 9 key targets were obtained (Figure 8C). Next, we predicted the docking efficiency between the above 5 active ingredients and the 9 key targets. The results indicated that the binding affinities between taxifolin and the targets HSP1A1, HSP90AB1 and PARP1 (docking energies of -9.25, -9.17 and -9.05 kcal/mol, respectively) were all higher than those between the remaining 4 components and other proteins (Figure 8D & Table 3). Therefore, taxifolin is very likely to be a potential key active component of CR in the treatment of CC; however, further experimental verification is needed.

Table 2
Identification of main ingredients in CR by UPLC-MS/MS data.

No.	t_R (min)	Molecular formula	Selected ion	Theoretical	Experimental	MS/MS fragmentations	Compounds
1	26.30	C ₉ H ₈ O ₂	[M-H] ⁺	148.16	149	130.74, 102.73	Cinnamic acid
2	11.70	C ₉ H ₈ O ₃	[M-H] ⁺	164.16	165	119.37, 90.92	2- Hydroxycinnamic acid
3	4.17	C ₇ H ₆ O ₄	[M-H] ⁻	154.12	153.51	109.14, 92.29, 80.73	Protocatechuic acid
4	6.93	C ₁₅ H ₁₄ O ₆	[M-H] ⁻	290.27	289.03	244.85, 202.74, 109.09	Catechinic acid
5	9.12	C ₁₅ H ₁₂ O ₇	[M-H] ⁻	304.25	302.85	192.91, 134.74	Taxifolin

Table 3

The results of molecular docking studies of five main ingredients in the active sites of nine proteins performed using AutoDock.

Proteins	Ligands				
	Cinnamic acid	2-Hydroxycinnamic acid	Protocatechuic acid	Catechinic acid	Taxifolin
PRKCA	-5.47	-5.83	-6.00	-7.44	-7.55
HSP90AB1	-7.33	-4.58	-6.88	-6.27	-9.17
APP	-5.68	-5.61	-5.09	-7.52	-8.04
RELA	-7.09	-6.72	-6.52	-7.10	-7.05
JUN	-4.20	-4.66	-3.98	-4.71	-5.21
MDM2	-5.49	-5.53	-5.13	-6.71	-6.83
PRKACA	-7.09	-6.81	-6.00	-7.93	-8.19
HSPA1A	-6.24	-5.52	-5.39	-7.56	-9.25
PARP1	-6.79	-6.62	-6.41	-8.62	-9.05
(kcal/mol)					

Discussion

Network pharmacology is an emerging discipline that studies the occurrence and development of diseases from the perspective of biological networks and investigates the mechanism of interaction between drugs and diseases, thereby guiding the development of new drugs. The study of the relationship between TCM and disease addresses holistic, synergistic and dynamic components, coinciding with the TCM perspectives of “holistic view” and “dialectical therapy”^[20]. Network pharmacology can elucidate the effect of drugs on biological networks from the perspective of macroscopic or overall regulation and provide novel research ideas and technical means for studying the mechanism of action of CHM^[21]. In recent years, we have carried out a series of basic studies using this advanced technology^[10, 18, 22, 23]. In this study, we first identified 14 potential active compounds in CR from the TCMSP database and related literature and explored the potential protein targets corresponding to these components. We also performed enrichment analysis of these targets. The results indicated that CR may play a role in the treatment of cancer. Next, given that the pharmacological mechanism of action of CR in the treatment of CC is currently unknown and the potential clinical application of CR has yet to be fully evaluated, we constructed a PPI systematic network for CR treatment of CC at the target level and identified 111 potential core targets. We further analyzed the potential molecular mechanism of CR action in the treatment of CC. Finally, a series of *in vivo* and *in vitro* experiments confirmed that CR could inhibit the growth of CC cells by negatively regulating the Akt/ERK signaling pathway, suggesting that CR has certain potential in the treatment of CC.

Next, we identified 5 potentially active monomers in CR via UPLC–MS/MS: cinnamic acid, 2-hydroxycinnamic acid, protocatechuic acid, catechinic acid, and taxifolin. Interestingly, previous studies have found that some

of the above components have potential antitumor effects. For example, cinnamic acid, as a key component in CR, can induce apoptosis in melanoma cells and reduce their proliferation rate, and its derivatives can also induce apoptosis in CC and cervical cancer cells^[24, 25]. Protocatechuic acid can inhibit the formation of melanin in melanoma cells; additionally, its combined application with 5-fluorouracil has been shown to promote antiproliferative and proapoptotic effects by inhibiting the colony formation ability of gastric cancer AGS cells^[26, 27]. Catechin compounds mainly include catechinic acid, epicatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate. Relevant studies have found that catechinic acid can increase the sensitivity of ovarian cancer cells to platinum-based drugs, and can damage DNA and reduce DNA synthesis to inhibit the proliferative activity of tumor cells^[28].

In addition, the results of the molecular docking showed that among the 45 docking systems, the top 3 binding systems involved the interactions between taxifolin and HSPA1A, HSP90AB1 and PARP1. Taxifolin, also known as dihydroquercetin, is a flavonoid. In recent years, the results of several studies have shown that taxifolin has an inhibitory effect on many types of tumors. For example, taxifolin inhibits diacylglycerol acyltransferase (DGAT) and microsomal triglyceride transfer protein (MTP) activity in human hepatocellular carcinoma (HepG2) cells, thus exerting an antihepatocarcinogenic effect; it also has a significant inhibitory effect on the colony-forming ability of HCT-116 human colon cancer cells^[29, 30]. Additionally, the abovementioned targets are also closely related to cancers. As a molecular chaperone, the expression level of heat shock protein 90 (Hsp90) in tumor cells is approximately 2-10 times that in normal cells. It has been reported that the expression of Hsp90 and its client proteins (e.g., EGFR, AKT, Raf-1, HER2, and CDK4/6), which are closely related to the development and progression of tumors, is increased^[31] and that the inhibition of Hsp90 function leads to the degradation of tumor-associated client proteins^[32]. Therefore, Hsp90 is a promising antitumor therapeutic target. A recent study found that the small molecule compound DCZ5248 is a novel dual inhibitor of Hsp90 and autophagy and has the potential to treat CC^[33]. Interestingly, related studies also showed that taxifolin can inhibit the expression of HSP90, thereby significantly reducing the growth and proliferation activity of breast cancer cells^[34]. There are approximately 17 members of the PARP family, and PARP1 is the most intensively studied member because of its broad application. Noshio et al. found that PARP1 was highly expressed in 70.3% of colorectal cancer tissues and that its expression level was correlated with tumor size and tumor differentiation. Another study also found that PARP1 was highly expressed in 68.2% of colorectal cancer tissues and closely associated with tumor location^[35, 36], indicating that high PARP1 expression may be an important molecular event in colorectal cancer. A study showed that protocatechuic acid could induce the apoptosis of ovarian cancer cells and inhibit their growth by increasing the expression of PARP protein in spliceosomes^[37]. Our WB results also showed that CR promoted the cleavage of PARP, thus inducing CC cell apoptosis. In summary, these results all support that CR shows potential as a multi-component, multi-target, and multi-pathway intervention option for the treatment of CC.

Conclusions

Our results show that CR can regulate the key biological functions and processes related to the growth and viability of CC cells, such as apoptosis and cell cycle. The interference of these may be attributed to the simultaneous inhibition of multiple signaling pathways, including Akt and ERK pathways. In addition, the molecular docking results also indicate that taxifolin may play an important role in the transmission of

pharmacological activities, and HSPA1A, HSP90AB1 and PARP1 are expected to become potential therapeutic targets of CR against CC (Supplementary Figure 3).

Abbreviations

CR: *Cinnamomi Ramulus*; CC: Colon cancer; TCM: Traditional Chinese medicine; CHM: Chinese herb medicine; PPI: Protein-protein interaction; UPLC-MS/MS: Ultraperformance liquid chromatography-tandem mass spectrometry; DC: Degree centrality; BC: Betweenness centrality; CC: Closeness centrality.

Declarations

Ethics approval and consent to participate:

The research protocols were approved by the Hospital Ethics Committee of Tianjin University ITCWM Hospital.

Consent for publication:

Not applicable.

Availability of data and materials:

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests:

The authors declare that they have no competing interests.

Funding:

This study was funded by the National Natural Science Foundation of China (grant no.81572416 & no.81802430), the National Key Technologies R&D Program of China (grant no.2016YFC1303200), and the Tianjin Science and Technology Commission Major Science and Technology Special Project for New Drug Development (grant no.18ZXXYSY00130).

Authors' contributions:

Shu Yan, Liren Liu and Senbiao Fang designed and supervised the study and finalized the manuscript. Boyu Pan, Yafei Xia, Zilu Gao, Gang Zhao and Liangjiao Wang contributed to the study design, performed the bioinformatics analysis and biological experiments and drafted the manuscript. All the authors approved the version to be published, and we have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgements:

Not applicable.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68:394–424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin.* 2017;67:7–30.
3. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin.* 2014;64:252–71.
4. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. *J Clin Oncol.* 2008;26:5721–7.
5. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, RGS M, Barzi A, Jemal A. Colorectal cancer statistics, 2017. *CA Cancer J Clin.* 2017;67:177–93.
6. Tang J, Liu B, Ma K. Traditional Chinese medicine. *Lancet* 2008;372:1938-40.
7. Kuo Y, Liao H, Chiang J, Wu M, Chen B, Chang C, Yeh M, Chang T, Sun M, Yeh C, Yen H. Complementary Chinese herbal medicine therapy improves survival of patients with pancreatic cancer in Taiwan: A nationwide population-based cohort study. *Integr Cancer Ther.* 2018; 17:411-22.
8. Editorial Committee of Chinese Pharmacopoeia (2015) *Chinese Pharmacopoeia*, vol. 1, 2015 edn. Beijing, China: China Medical Science and Technology Press, pp 276.
9. Dai Y, Qiang W, Yu X, Cai S, Lin K, Xie L, Lan X, Wang D. Guizhi Fuling decoction inhibiting the PI3K and MAPK pathways in breast cancer cells revealed by HTS² technology and systems pharmacology. *Comput Struct Biotechnol J.* 2020;18:1121-36.
10. Pan B, Wang Y, Wu C, Jia J, Huang C, Fang S, Liu L. A mechanism of action study on Danggui Sini Decoction to discover its therapeutic effect on gastric cancer. *Front Pharmacol.* 2021;11:592903.
11. Zhang G, Li Q, Chen Q, Su S. Network pharmacology: a new approach for Chinese herbal medicine research. *Evid Based Complement Altern Med.* 2013;2013:621423.
12. Yuan H, Ma Q, Cui H, Liu G, Zhao X, Li W, Piao G. How can synergism of traditional medicines benefit from network pharmacology? *Molecules.* 2017;22:1135.
13. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. *Chin J Nat Med.* 2013;11:110–20.
14. Shin S, Lee S, Lee E, Kim K, Byun S. Caffeic acid phenethyl ester from the twigs of *Cinnamomum cassia* inhibits malignant cell transformation by inducing c-Fos degradation. *J Nat Prod.* 2017;80:2124–30.
15. Sara S, Helia R, Athareh P, Elham J, Behjat K. Effect of Cinnamic acid and FOLFOX in diminishing side population and downregulating cancer stem cell markers in colon cancer cell line HT-29. *Daru.* 2018;26:19-29.
16. Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y, Xu X, Li Y, Wang Y, Yang L. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. *J Cheminform.* 2014;6:13.
17. Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.*

2003;13:2498-504.

18. Pan B, Zang J, He J, Wang Z, Liu L. Add-On therapy with Chinese herb medicine Bo-Er-Ning capsule (BENC) improves outcomes of gastric cancer patients: a randomized clinical trial followed with bioinformatics-assisted mechanism study. *Am J Cancer Res.* 2018;8:1090-105.
19. Pan B, Shi X, Ding T, Liu L. Unraveling the action mechanism of *polygonum cuspidatum* by a network pharmacology approach. *Am J Transl Res.* 2019;11:6790-811.
20. Luo T, Lu Y, Yan S, Xiao X, Rong X, Guo J. Network pharmacology in research of Chinese medicine formula: methodology, application and prospective. *Chin J Integr Med.* 2020;26:72-80.
21. Da C, Pei G. Network pharmacology: a rosetta stone for traditional Chinese medicine. *Drug Dev Res.* 2014;75:299-312.
22. Pan Y, Chen Y, Wu C, Ai J, Wang Y, Jia J, Liu L. Network pharmacology-guided mechanism study uncovers inhibitory effect of Mahuang Decoction on lung cancer growth by impeding Akt/ERK signaling pathways. *Am J Transl Res.* 2021;13:2094-110.
23. Pan B, Fang S, Zhang J, Pan Y, Liu H, Wang Y, Li M, Liu L. Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor. *Comput Struct Biotechnol J.* 2020;18:3518-27.
24. Niero E, Machado-Santelli G. Cinnamic acid induces apoptotic cell death and cytoskeleton disruption in human melanoma cells. *J Exp Clin Cancer Res.* 2013;32:31.
25. Anantharaju P, Reddy D, Padukudru M, Kumari Chitturi C, Vimalambike M, Madhunapantula S. Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC). *PLoS One.* 2017;12:e0186208.
26. Truong X, Park S, Lee Y, Jeong H, Moon J, Jeon T. Protocatechuic acid from pear inhibits melanogenesis in melanoma cells. *Int J Mol Sci.* 2017;18:1809.
27. Motamedi Z, Amini SA, Raeisi E, Lemoigne Y, Heidarian E. Combined Effects of Protocatechuic Acid and 5-Fluorouracil on p53 Gene Expression and Apoptosis in Gastric Adenocarcinoma Cells. *Turk J Pharm Sci.* 2020;17:578-85.
28. Yunos N, Beale P, Yu J, Huq F. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. *Anticancer Res.* 2011;31:1131-40.
29. Casaschi A, Rubio B, Maiyoh G, Theriault A. Inhibitory activity of diacylglycerol acyltransferase (DGAT) and microsomal triglyceride transfer protein (MTP) by the flavonoid, taxifolin, in HepG2 cells: potential role in the regulation of apolipoprotein B secretion. *Atherosclerosis.* 2004;176:247-53.
30. Woo Y, Shin S, Hyun J, Lee S, Lee Y, Lim Y. Flavanones inhibit the clonogenicity of HCT116 colorectal cancer cells. *Int J Mol Med.* 2012;29:403-8.
31. Isaacs J, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. *Cancer Cell.* 2003;3:213–7.
32. Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J 3rd, Modi S, Chiosis G. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. *Expert Opin Investig Drugs.* 2014;23:611–28.

33. Chen X, Liu P, Zhu W, Lou L. DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer. *Acta Pharmacol Sin.* 2021;42:132-41.
34. Li X, Lu J, Zhang L, Luo Y, Zhao Z, Li M. Clinical implications of monitoring ESR1 mutations by circulating tumor DNA in estrogen receptor positive metastatic breast cancer: a pilot study. *Transl Oncol.* 2020;13:321.
35. Noshio K, Yamamoto H, Mikami M, Taniguchi H, Takahashi T, Adachi Y, Imamura A, Imai K, Shinomura Y. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. *Eur J Cancer.* 2006;42:2374-81.
36. Sulzyc-Bielicka V, Domagala P, Hybiak J, Majewicz-Broda A, Safranow K, Domagala W. Colorectal cancers differ in respect of PARP-1 protein expression. *Pol J Pathol.* 2012;63:87-92.
37. Xie Z, Guo Z, Wang Y, Lei J, Yu J. Protocatechuic acid inhibits the growth of ovarian cancer cells by inducing apoptosis and autophagy. *Phytother Res.* 2018;32:2256-63.

Figures

Figure 1

Figure 1

Construction of the CR compound-target systematic network and enrichment analyses of the putative targets . (A) The physical map of CR. (B) The 14 potential active compounds in CR. (C) The systematic network was constructed by linking the potential active compounds and their putative drug targets in CR. (D) & (E) Putative drug targets were enriched in the KEGG pathway and disease using DAVID v6.8 and KOBAS 3.0, respectively ($p < 0.05$).

Figure 2

Figure 2

CR suppressed development of the xenografted CC tumors on C57BL/6 mice. (A) Workflow for this in vivo assay. (B) & (C) The photos of tumor sizes were shown on the day 14. (D) The tumor volumes were measured and calculated once daily for 14 consecutive days. (E) The tumors were resected and weighted on the day 14. (F) The body weight were measured once daily for 14 consecutive days. (G) H&E and immunohistochemistry staining for Ki-67 were performed by using the tumor slides from control and CR-treated groups. * $p < 0.05$ and ** $p < 0.01$ based on the Student's t-test.

Figure 3

A

B

C

D

Figure 3

CR inhibited CC cells growth and decreased its viability. (A) CCK-8 assay was performed to measure cell viability at 24h and 48h after CR treatment at different dosages (0,0.1,0.2,0.4,0.6,0.8,1.0 mg/mL). (B) CCK-8 assay was performed to measure cell growth ability at 24h and 48h after CR treatment at 24h IC₅₀ (0.27 mg/mL and 0.12 mg/mL) in HT-29 and HCT-15 cells, respectively. (C) Cell colony formation assay was performed to measure cell clonality after CR treatment for 24h. ***p<0.001 and ****p<0.0001 based on the Student's t-test. (D) The Operetta CLS High Content Analysis System was used to evaluate the accumulated distance of CC cells at 24h after CR treatment. **p<0.01 and ***p<0.001 based on the Student's t-test.

Figure 4

A

B

C

Figure 4

The known CC-related targets were screened from Gene Expression Omnibus (GEO) database. (A) Two heat maps from GEO chips, including GSE44076 and GSE13471. (B) The Venn diagram of 114 common CC-related targets from two GEO chips. (C) Construction of the CC-related targets systematic network.

Figure 5

A

B

C

Figure 5

Screening the candidate core targets for CR against CC and enrichment analyses. (A) (i) The PPI network of CR putative targets was made of 5575 nodes and 103469 edges. (ii) The PPI network of CC-related targets was composed of 2027 nodes and 34539 edges. (iii) The PPI network of CR against CC- related targets was made of 1181 nodes and 22173 edges. (iv) The PPI network of key targets extracted from iii, in which 300 nodes and 8604 edges were shown. (v) The PPI network of candidate core targets extracted from iv, in which 111 nodes and 2312 edges were shown. (B) Candidate core targets were enriched in the representative

biological processes (GO) by using Metascape ($p < 0.05$). (C) Candidate core targets were enriched in the representative signaling pathways (KEGG) by using DAVID v6.8 ($p < 0.05$).

Figure 6

Figure 6

CR treatment resulted in apoptosis and disturbance of cell cycle progression in CC cells. (A) The cell morphology was observed in white light and fluorescence field using an inverted microscope. (B) Induction of apoptosis of HT-29 and HCT-15 cells after CR treatment for 24h. The apoptotic events was assessed by flow cytometry. (C) & (D) Statistical analysis of the percentages of the apoptotic cells in HT-29 and HCT-15 cells. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ based on the Student's t-test. (E) Cell cycle analysis of HT-29 and HCT-15

cells following CR treatment for 24h by flow cytometry. (F) & (G) Statistical analysis of the proportions of the cells at different phases in HT-29 and HCT-15 cells. * $p<0.05$ and *** $p<0.001$ based on the Student's t-test. (H) HT-29 and HCT-15 cells were treated with CR at different concentrations for 24h. After proteins were extracted, the expression levels of Bcl-2, Bax, pro-caspase-9, cleaved-caspase-9, pro-PARP, cleaved-PARP, Cyclin D1, CDK2, CyclinA2 and CyclinB1 were analyzed by WB assay, respectively.

Figure 7

Figure 7

Down-regulating the phosphorylation protein expression level of Akt and ERK signaling pathways with CR treatment. HT-29 and HCT-15 cells were treated with CR at different concentrations for 24h. After proteins were extracted, the expression levels of p-Akt (T308), p-Akt (S473) and p-ERK (T202/Y204) were analyzed by WB assay, respectively.

Figure 8

Figure 8

Five main ingredients obtained from CR by using UPLC-MS/MS and molecular docking analysis by AutoDock. (A) (i) The ultraviolet absorption wavelength map. (ii) The total ion chromatography (TICs) in positive ion modes. (iii) The total ion chromatography (TICs) in negative ion modes. (B) The five main ingredients were identified by secondary mass spectrometry. (C) The Venn diagram of 9 common key core targets from CR-related targets and candidate core targets. (D) Binding modes from AutoDock 4.2. Taxifolin with HSP1A1, HSP90AB1 and PARP1, respectively.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigure1.tif](#)
- [SupplementaryFigure2.tif](#)
- [SupplementaryFigure3.tif](#)
- [SupplementaryTable1.ThecandidatedrugtargetsofCR.xlsx](#)
- [SupplementaryTable2.TheCCrelatedtargetsfromGEO.xlsx](#)
- [SupplementaryTable3.Thepotentialcoretargets.xlsx](#)